Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Chief Medical Officer Rodman David Malcom executed two separate sales of company common stock totaling $556,671 on July 13 and July 15, 2026. The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on October 6, 2025. Concurrently with the initial sale on July 13, Mr. Malcom also exercised stock options totaling $102,365. Following these transactions, he retains direct ownership of 51,384 shares. The sales occurred as the stock traded at $27.33, with platform data indicating a 5.7% weekly decline and suggesting the stock may be overvalued relative to fair value metrics.
The first transaction took place on July 13, 2026, when Mr. Malcom sold 14,058 shares of Mineralys Therapeutics common stock. The weighted-average price for this sale was $27.5798 per share, with individual transaction prices ranging from $26.965 to $27.750. Two days later, on July 15, 2026, an additional 6,349 shares were sold at a weighted-average price of $26.6112 per share. Transaction prices for this second sale ranged from $26.41 to $27.15.
Simultaneously with the initial sales on July 13, 2026, Mr. Malcom acquired common stock through the exercise of stock options, totaling $102,365. This acquisition included 3,542 shares acquired at an exercise price of $10.20 per share, 4,167 shares at $14.25 per share, and 6,349 shares at $1.08 per share. The options exercised had varying vesting schedules; some vested in monthly installments over a four-year period, while others vested 25% on the first anniversary of the grant date, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Following these reported transactions, Rodman David Malcom directly holds 51,384 shares of Mineralys Therapeutics common stock. For deeper insights into MLYS's financial health and insider activity patterns, InvestingPro offers 7 additional ProTips and a comprehensive Pro Research Report covering this $2.4 billion biotech company.
Mineralys Therapeutics has been actively managing its financial position through recent strategic initiatives. The company announced a public offering of 5,660,378 shares of common stock priced at $26.50 per share, aiming to raise approximately $150 million in gross proceeds. Additionally, the company secured $750 million through a combination of debt, equity, and a royalty deal to strengthen its financial position. This included a payment to Tanabe Pharma Corporation to eliminate future royalty obligations related to lorundrostat, with Tanabe assigning its intellectual property rights to Mineralys.
Market analysts have provided mixed perspectives on the company's prospects. Analyst firm Jefferies reiterated a Hold rating on Mineralys stock, citing potential acquisition interest as the company's new drug application undergoes FDA review. Meanwhile, H.C. Wainwright maintained a Buy rating, highlighting data presented by Mineralys at a European conference, which focused on lorundrostat's efficacy in treating hypertension. Mineralys also shared clinical data from the Phase 3 Launch-HTN trial, revealing that lorundrostat was evaluated in patients with uncontrolled or resistant hypertension, including those with chronic kidney disease.
Mineralys Therapeutics stock price data indicates a current trading price of $27.33, with a change of +$0.05 (+0.18%) at 15:59:59 USD. After hours trading shows a price of $27.30, with a change of -$0.01 (-0.04%) at 19:12:22. The stock has experienced a 5.7% decline over the past week, according to InvestingPro data. The platform's Fair Value analysis suggests the stock is currently overvalued.
Mineralys Therapeutics continues to advance its drug portfolio and financial strategy. The company's efforts to secure funding and manage royalty obligations reflect its ongoing commitment to supporting the development of lorundrostat. The clinical data presented at the European conference and the Phase 3 Launch-HTN trial provide further insight into the drug's potential applications in treating hypertension, including in patients with chronic kidney disease.